Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

Regeneron Pharmaceuticals

Overview

Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.

Expanded Access requests are only being considered in response to Individual Patient and Intermediate-Size Population EAP Investigational New Drug (IND) applications. Availability will depend on location.

Study Type

EXPANDED_ACCESS

Conditions

Lipodystrophy Generalized Lipodystrophy (GLD)Monogenic Obesity (MOB)

Interventions

REGN4461DRUG

To be provided by Regeneron

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Key Inclusion: N/A Key Exclusion: N/A

Central Contacts

Requests for Expanded Access must be initiated by a treating physician. Physicians should contact

CONTACT

844-734-6643 Managedaccessrequests@regeneron.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.